Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$110.4M
60M shares
52-week range
$1.07 – $6.18
19% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $71.0K | $96.3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$71.0K | −$96.3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $29.8M | $44.4M | $24.7M | $44.9M | $47.3M | $29.5M | $48.2M | $25.7M |
| Operating income | −$39.7M | −$63.1M | −$36.4M | −$56.2M | −$62.7M | −$42.8M | −$60.1M | −$35.3M |
| EBITDA | −$38.7M | −$61.4M | −$34.3M | −$55.8M | −$60.1M | −$35.2M | −$53.7M | −$31.7M |
| Net income | −$38.9M | −$60.8M | −$37.6M | −$57.8M | −$62.0M | −$37.5M | −$55.9M | −$33.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.79 | -2.24 | -1.11 | -1.07 | -1.06 | -0.64 | -0.94 | -0.56 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.33 | $-0.33–$-0.33 | 2 |
| 2027 | $11M | $-0.21 | $-0.21–$-0.21 | 3 |
| 2028 | $42M | $-0.03 | $-0.06–$0.00 | 2 |
| 2029 | $64M | $0.15 | $0.15–$0.15 | 1 |
Forward consensus · source: Financial Modeling Prep
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
www.aldeyra.comNo one on the platform currently holds ALDX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 863,187 | $1.5M |
No one on the platform has traded ALDX yet.
| $569M |
| — |
| CLLSCellectis S.A. | $2.94 | +3.89% | $295M | — |
| CTNMContineum Therapeutics, Inc. | $15.00 | +5.71% | $561M | — |
Source: Financial Modeling Prep · peers by sector/industry
$TNMG $ALDX $KULR $ANGX $LCID = Amazing work everyone! This was a great session for these stocks. These were our best movers this round! We are bullish and expecting even more momentum on these names going into Tuesday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great rest of the day everybody! 🎉
View on StockTwits ↗$ALDX man so many -$100,000 position holders here it's sad.. Todd should go to jail...
View on StockTwits ↗$ALDX this is kind of insane how long its taking to hear something
View on StockTwits ↗$ALDX Latest News: the appointment of Darlene Deptula-Hicks Pipeline: Reproxalap Topical ocular administration (Option agreement w/AbbVie) Dry Eye Disease Preclinical Phase 1Phase 2Phase 3 all passed Reproxalap Topical ocular administration (Option agreement w/AbbVie) Allergic Conjunctivitis PreclinicalPhase 1Phase 2Phase 3 all passed Now is there something else to know before loading up. What is the estimated timelime before FDA approval? Is this stock the next $OTLK ?? Waiting your comments, Cheers...
View on StockTwits ↗$ALDX the resilience of this stock is something else...what are people expecting resolution to be? At the fireside, he essentially said an appeal is the most likely outcome after Type A meeting; is the expectation that OND will be more lenient than the OSM?
View on StockTwits ↗$ALDX Thought we have been clearing out key resistance this morning.... poop... adding more down here...
View on StockTwits ↗$ALDX Every time the FDA shows a willingness to think ($RGNX being the latest), this stock should edge up. Todd has had their meeting, we are waiting on the minutes. If they do a formal dispute resolution, then it probably bodes well to track finally to an approval with just a label discussion, like $OTLK.
View on StockTwits ↗$OTLK $ALDX $GPUS $IREN lol short those little guy...let me see how quick you blow your account !!
View on StockTwits ↗$ALDX $GPUS $IREN $OTLK I’ve been following and you are always wrong
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.